ICU Medical, Inc. (FRA:IC7)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.80B -10.3% |
| Revenue (ttm) | 1.87B -10.9% |
| Net Income | 40.19M |
| EPS | 1.61 |
| Shares Out | n/a |
| PE Ratio | 69.68 |
| Forward PE | 15.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 111.00 |
| Previous Close | 113.00 |
| Day's Range | 111.00 - 112.00 |
| 52-Week Range | 92.00 - 136.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About ICU Medical
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinf... [Read more]
News
ICU Medical upgraded to Buy from Hold at Needham
Needham upgraded ICU Medical (ICUI) to Buy from Hold with a $165 price target The firm expects the company to benefit from an IV system replacement cycle as well as…
ICU Medical Transcript: AGM 2026
The meeting saw the election of all director nominees, approval of auditor ratification, executive compensation, and key governance amendments, including a 25% threshold for special meetings. A shareholder proposal for a 10% threshold was not approved.
ICU Medical reports Q1 adjusted EPS $1.72, consensus $1.75
Reports Q1 revenue $530.23M, consensus $531.12M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “First quarter results were generally in line with our expectations.”
ICU Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 1% organic revenue growth, record IV Systems sales, and 41% gross margin. Adjusted EPS rose 15% to $1.97, and guidance for the year remains unchanged despite oil and tariff headwinds. Integration costs are declining, and innovation continues in core businesses.
ICU Medical Earnings release: Q1 2026
ICU Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
ICU Medical Quarterly report: Q1 2026
ICU Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
ICU Medical Slides: Q1 2026
ICU Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
ICU Medical Announces First Quarter 2026 Results
SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial resu...
ICU Medical price target lowered to $164 from $180 at KeyBanc
KeyBanc lowered the firm’s price target on ICU Medical (ICUI) to $164 from $180 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes…
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of...
ICU Medical price target lowered to $163 from $178 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on ICU Medical (ICUI) to $163 from $178 and keeps an Overweight rating on the shares. In addition to updated…
ICU Medical Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has evolved into a global pure-play infusion leader, leveraging innovation and market consolidation for growth. Consumables and infusion systems segments are driving reliable earnings, with new products and software enhancing value. Margin expansion, tariff refunds, and share repurchases are key financial priorities.
ICU Medical Proxy statement: Proxy filing
ICU Medical filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
ICU Medical Proxy statement: Proxy filing
ICU Medical filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
ICU Medical Proxy statement: Proxy filing
ICU Medical filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.
ICU Medical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management reaffirmed EBITDA guidance and mid-single-digit growth for core segments, with margin expansion expected as integration and cost initiatives progress. Pump upgrades and consumables innovation are key drivers, while free cash flow and capital returns should improve as integration costs decline.
ICU Medical Transcript: 47th Annual Raymond James Institutional Investor Conference
A leading infusion therapy company highlighted its strong market position, ongoing innovation, and financial recovery post-acquisition. New unified pump platforms and incremental consumables innovation are driving growth, with margin expansion and improved cash flow expected as integration and tariff costs decline.
ICU Medical Slides: 47th Annual Raymond James Institutional Investor Conference
ICU Medical has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its particip...
ICU Medical price target raised to $178 from $172 at Piper Sandler
Piper Sandler raised the firm’s price target on ICU Medical (ICUI) to $178 from $172 and keeps an Overweight rating on the shares following quarterly results. Guidance for 2026 bracketed…
ICU Medical price target raised to $180 from $175 at KeyBanc
KeyBanc analyst Brett Fishbin raised the firm’s price target on ICU Medical (ICUI) to $180 from $175 and keeps an Overweight rating on the shares given higher estimates. The firm…
ICU Medical sees FY26 adjusted EPS $7.75-$8.45, consensus $8.01
Sees FY26 adjusted EBITDA $400M-$430M. The company said, “For fiscal year 2026 the Company estimates GAAP net income to be in the range of $26 million to $44 million and…
ICU Medical Earnings Call Transcript: Q4 2025
Q4 2025 saw 2% organic revenue growth and strong operational results in consumables and systems, despite reported declines from JV deconsolidation and tariff headwinds. 2026 guidance calls for low- to mid-single-digit organic growth, margin expansion, and improved free cash flow as integration projects conclude.
ICU Medical Annual report: Q4 2025
ICU Medical has published its Q4 2025 annual report on February 19, 2026.
ICU Medical Earnings release: Q4 2025
ICU Medical released its Q4 2025 earnings on February 19, 2026, summarizing the period's financial results.